Novacyt Stock

Novacyt Total Assets

The Total Assets of Novacyt (ALNOV.PA) as of Sep 5, 2026 is 70.63 M GBP. In the previous year, Total Assets was 133.82 M GBP — a change of -47.22% (lower).

Total Assets

70.63 MGBP

YoY

-47.22%

Last updated:

Total Assets of Novacyt is 2026 70.63 M GBP. Total Assets of Novacyt was 2025 133.82 M GBP. It decreases by -47.22% lower compared to the previous year.

The Novacyt Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2017
29.53 M GBP
Jan 1, 2018
29.32 M GBP
Jan 1, 2019
26.53 M GBP
Jan 1, 2020
234.28 M GBP
Jan 1, 2021
183.70 M GBP
Jan 1, 2022
140.90 M GBP
Jan 1, 2023
133.82 M GBP
Jan 1, 2024
70.63 M GBP
The Novacyt Total Assets history
YEARTotal AssetsYoY
70.63 MGBP-47.22%
133.82 MGBP-5.03%
140.90 MGBP-23.30%
183.70 MGBP-21.59%
234.28 MGBP+783.16%
26.53 MGBP-9.52%
29.32 MGBP-0.71%
29.53 MGBP+12.80%
26.18 MGBP+53.02%
17.11 MGBP-35.81%
26.65 MGBP
Access this data via the Eulerpool API

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Total Assets of Novacyt is 70.63 M GBP in 2026.

Total Assets of Novacyt changed from 133.82 M GBP to 70.63 M GBP, representing a -47.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Novacyt since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Novacyt historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Novacyt

All Key Metrics — Novacyt